| Pharmaceutical Information |
| Drug Name |
Ibandronic acid |
| Drug ID |
BADD_D01117 |
| Description |
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138]
Ibandronate was granted FDA approval on 16 May 2003.[L13805] |
| Indications and Usage |
For the treatment and prevention of osteoporosis in postmenopausal women.[L13805,L13808] |
| Marketing Status |
approved; investigational |
| ATC Code |
M05BA06 |
| DrugBank ID |
DB00710
|
| KEGG ID |
D08056
|
| MeSH ID |
D000077557
|
| PubChem ID |
60852
|
| TTD Drug ID |
D08SJZ
|
| NDC Product Code |
Not Available |
| UNII |
UMD7G2653W
|
| Synonyms |
Ibandronic Acid | Ibandronate | 1-Hydroxy-3-(methylpentylamino)propylidenebisphosphonate | (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonate | Ibandronate Sodium Anhydrous | Boniva | Bonviva | Ibandronate Sodium | Ibandronic Acid, Sodium Salt, Monohydrate | RPR 102289A | RPR-102289A | RPR102289A | Bondronat | BM 21.0955 | BM 210955 | BM-21.0955 | BM21.0955 | BM-210955 | BM210955 |
|
| Chemical Information |
| Molecular Formula |
C9H23NO7P2 |
| CAS Registry Number |
114084-78-5 |
| SMILES |
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
